Methotrexate Should NOT Be Completely Stopped in Rheumatoid Arthritis Patients in Sustained Remission
In patients with rheumatoid arthritis who have achieved sustained remission with no active symptoms, methotrexate can be tapered but should not be completely discontinued. This recommendation is based on the highest-level guideline evidence prioritizing long-term disease control and prevention of flare.
Guideline-Based Approach
The 2022 EULAR recommendations explicitly state: "With sustained remission, DMARDs may be tapered but should not be stopped" 1. This represents the current gold-standard approach and directly answers your question. The 2020 EULAR guidelines similarly recommend that "if a patient is in persistent remission, tapering the csDMARD could be considered" - note the word "tapering," not stopping 2.
Key Decision Points
What Constitutes "Sustained Remission"?
- Must be in persistent remission after glucocorticoids have been tapered off
- Remission should be sustained over time (typically 6+ months of stable disease activity)
- This applies to patients on methotrexate monotherapy or combination therapy
The Tapering Strategy (Not Stopping)
If on methotrexate monotherapy:
- Gradual dose reduction is preferred over complete discontinuation
- Close monitoring every 1-3 months during tapering 2
- Be prepared to escalate back to full dose if disease activity returns
If on combination therapy (methotrexate + biologic/JAK inhibitor):
- The 2020 EULAR guidelines recommend tapering the biologic/tsDMARD FIRST before considering methotrexate reduction 2
- Methotrexate should be maintained as the "anchor" therapy
Evidence Supporting Caution Against Complete Discontinuation
A 2023 systematic review and meta-analysis found that patients who tapered methotrexate from targeted therapy had a 10% reduction in ability to sustain remission (pooled risk ratio 0.90,95% CI 0.84-0.97) 3. While this may seem modest, it represents a meaningful risk of disease flare that could lead to:
- Joint damage progression
- Functional decline
- Need for treatment escalation
The 2021 study comparing etanercept vs methotrexate withdrawal showed that methotrexate monotherapy maintained remission in only 28.7% of patients at 48 weeks when etanercept was stopped, with significantly shorter time to disease worsening 4. This underscores that methotrexate alone may not be sufficient after achieving remission on combination therapy, but complete withdrawal is even riskier.
Critical Caveats and Pitfalls
Common Mistake: Stopping Too Abruptly
- Never stop methotrexate cold turkey in a patient who achieved remission on it
- Even in "perfect" remission, RA is a chronic disease that cannot be cured 2
Monitoring During Any Dose Reduction
- Assess disease activity every 1-3 months during tapering 2
- If any increase in disease activity occurs, immediately return to the previous effective dose
- Don't wait for full flare - early intervention prevents joint damage
Patient Selection for Tapering Attempts
Consider attempting cautious tapering (not stopping) in patients with:
- Prolonged remission (>12 months)
- No poor prognostic factors (negative RF/ACPA, no erosions)
- Good adherence and ability to monitor symptoms
- Understanding that dose may need to be increased again
Absolute Contraindications to Stopping
Do NOT attempt to taper/stop methotrexate in patients with:
- Recent achievement of remission (<6-12 months)
- History of aggressive disease or rapid flares
- Presence of erosive disease
- High-titer autoantibodies (RF, anti-CCP)
The Bottom Line Algorithm
- Sustained remission achieved → Consider tapering (not stopping) after 6-12+ months
- On combination therapy → Taper biologic/JAK inhibitor FIRST, maintain methotrexate 2
- On methotrexate monotherapy → Gradual dose reduction with close monitoring
- Any disease activity increase → Immediately return to previous effective dose
- Complete discontinuation → Not recommended per current guidelines 2, 1
The 2022 EULAR guidelines carry the highest level of evidence (Level 1a) and strongest recommendation grade for this approach 1. This strategy balances reducing medication burden against the real risk of disease flare and subsequent joint damage.